文献速递糖尿病

鉴定1型糖尿病基因靶点的下一步方向

Next steps in the identification of gene targets for type 1 diabetes.
PubMed 文献 · Diabetologia · 2020-08-14

本综述展望基因组学及其他组学方法在界定1型糖尿病各风险阶段的遗传贡献、相关变异的功能影响及临床转化中的应用;指出已识别超过60个含SNPs的1型糖尿病风险位点,与HLA区域基因合计可解释约50%的遗传风险,但多数变异位于非编码调控区。

要点

  • 已识别超过60个含SNPs的1型糖尿病风险位点,与HLA区域基因合计可解释约50%的总遗传风险。
  • 绝大多数遗传风险变异位于基因调控区域,而非编码区,其靶效应分子不易直接识别。
  • 联合免疫与β细胞来源的变异构建遗传风险评分,为1型糖尿病的预测和治疗开辟新途径。

核心结论

  • 联合免疫与β细胞来源的变异构建遗传风险评分,为1型糖尿病的预测和治疗开辟新途径。

研究设计与样本

  • 本文为综述,回顾近50年来从HLA区分1型与2型糖尿病风险到通过技术进展与协作样本采集识别超过60个含SNPs的1型糖尿病风险位点的遗传学研究。

主要发现

  • 超过60个含SNPs的位点与1型糖尿病风险相关,与HLA区域基因合计可解释约50%的总遗传风险。
  • 相对少数变异位于基因编码区并预测蛋白改变,绝大多数遗传风险归因于参与基因调控的基因组区域。
  • 过去遗传研究明确涉及免疫相关细胞类型,但靶器官β细胞未被触及。
  • 通过遗传学、基因表达、表观遗传学、染色体构象和基因编辑等技术,揭示了SNPs调控基因的新景观。
  • 免疫系统和β细胞及其生物学通路以背景特异性方式被关联。

关键数值与推荐

  • 与HLA区域基因合计,超过60个含SNPs的位点可解释约50%的总遗传风险。

局限性

  • 绝大多数遗传风险变异位于基因调控区域,其靶效应分子不易直接识别。
  • 过去遗传研究虽明确涉及免疫相关细胞类型,但靶器官β细胞未被触及。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The purpose of this review is to provide a view of the future of genomics and other omics approaches in defining the genetic contribution to all stages of risk of type 1 diabetes and the functional impact and clinical implementations of the associated variants. From the recognition nearly 50 years ago that genetics (in the form of HLA) distinguishes risk of type 1 diabetes from type 2 diabetes, advances in technology and sample acquisition through collaboration have identified over 60 loci harbouring SNPs associated with type 1 diabetes risk. Coupled with HLA region genes, these variants account for the majority of the genetic risk (~50% of the total risk); however, relatively few variants are located in coding regions of genes exerting a predicted protein change. The vast majority of genetic risk in type 1 diabetes appears to be attributed to regions of the genome involved in gene regulation, but the target effectors of those genetic variants are not readily identifiable. Although past genetic studies clearly implicated immune-relevant cell types involved in risk, the target organ (the beta cell) was left untouched. Through emergent technologies, using combinations of genetics, gene expression, epigenetics, chromosome conformation and gene editing, novel landscapes of how SNPs regulate genes have emerged. Furthermore, both the immune system and the beta cell and their biological pathways have been implicated in a context-specific manner. The use of variants from immune and beta cell studies distinguish type 1 diabetes from type 2 diabetes and, when they are combined in a genetic risk score, open new avenues for prediction and treatment. Graphical abstract.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Grant SFA, Wells AD, Rich SS, et al. Next steps in the identification of gene targets for type 1 diabetes. Diabetologia. 2020. PMID: 32797243. doi:10.1007/s00125-020-05248-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。